IP Library › Granted Patent US 12,226,415
Granted Patent B2
US 12,226,415 · App. 17/632,973 · Granted Feb 18, 2025

Methods and compositions for the treatment of hair loss

Inventor: John Edward Wurst (Poway, CA)
Assignee: Aneira Pharma, Inc.
A61K31/506A61K9/0014A61K31/222A61K31/25A61K31/5575A61K31/58A61K38/13A61K47/10A61K47/12A61K47/26A61P17/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,415
App. No.
17/632,973
Granted
Feb 18, 2025
Kind
B2
Abstract

Compositions and methods for the treatment of hair growth and the prevention of hair loss.

Claims (10)

1. A composition for use in the treatment of hair loss comprising about 0.05%-0.5% w/v latanoprost and latanoprost acid and 0.01%-0.1% w/v cyclosporine.

2. The composition of claim 1 further comprising oleyl alcohol or ethanol.

3. The composition of claim 2 further comprising one selected from the group consisting of polyethylene glycol or propylene glycol.

4. The composition of claim 3 further comprising acetic acid and one selected from the group consisting of polysorbate 60 and polyoxyethylene lauryl alcohol.

5. The composition of claim 3 further comprising acetic acid one selected from the group consisting of polysorbate 60 and polyoxyethylene lauryl alcohol.

6. The composition of claim 2 further comprising ethanol and at least one selected form the group consisting of propylene glycol and polysorbate 80.

7. The composition of claim 1 wherein ethanol is present in a concentration of about 25%-30% w/v.

8. The composition of claim 1 wherein the composition further comprises oleyl alcohol.

9. The composition of claim 3 further comprising diethylene glycol monoethyl ether.

10. The composition of claim 1 , wherein the composition is useful for treating alopecia areata.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2022
From: WURST, JOHN EDWARD
To: ANEIRA PHARMA, INC.
Reel/Frame 058892/0942 →
Continuity (4)
Provisional Application 63100611 · Mar 23, 2020
Provisional Application 62895869 · Sep 4, 2019
Provisional Application 62883809 · Aug 7, 2019
Related Publication 20220288090A1 · Sep 15, 2022
References Cited (107)
US 4139619A · Chidsey, III · 1979 [cited by applicant]
US 4596812A · Chidsey, III et al. · 1986 [cited by applicant]
US 4820512A · Grollier · 1989 [cited by applicant]
US 4828837A · Uster et al. · 1989 [cited by applicant]
US 5030442A · Uster et al. · 1991 [cited by applicant]
US 5225189A · Pena · 1993 [cited by applicant]
US 5407944A · Goldman · 1995 [cited by applicant]
US 5620980A · Samour · 1997 [cited by applicant]
US 5834014A · Weiner et al. · 1998 [cited by applicant]
US 6262105B1 · Johnstone · 2001 [cited by applicant]
US 6403649B1 · Woodward et al. · 2002 [cited by applicant]
US 6465514B1 · Hallam et al. · 2002 [cited by applicant]
US 6596266B2 · Catalfo et al. · 2003 [cited by applicant]
US 6946120B2 · Wai-Chiu So et al. · 2005 [cited by applicant]
US 7388029B2 · Delong et al. · 2008 [cited by applicant]
US 7442369B1 · Pena et al. · 2008 [cited by applicant]
US 7749489B2 · Malek · 2010 [cited by applicant]
US 7803357B2 · Cappello · 2010 [cited by applicant]
US 8038988B2 · Woodward et al. · 2011 [cited by applicant]
US 8293789B2 · Jimenez-Bayardo et al. · 2012 [cited by applicant]
US 8454945B2 · Mccook et al. · 2013 [cited by applicant]
US 8758733B2 · Ahluwalia et al. · 2014 [cited by applicant]
US 8906962B2 · Delong et al. · 2014 [cited by applicant]
US 9138480B2 · Trogden et al. · 2015 [cited by applicant]
US 9149484B2 · Warner et al. · 2015 [cited by applicant]
US 9226931B2 · Ahluwalia et al. · 2016 [cited by applicant]
US 9700503B2 · Woodward et al. · 2017 [cited by applicant]
US 9750750B2 · Trogden et al. · 2017 [cited by applicant]
US 9763359B2 · Chan · 2017 [cited by applicant]
US 9849140B2 · Warner et al. · 2017 [cited by applicant]
US 10188661B2 · Singer et al. · 2019 [cited by applicant]
US 10470992B2 · Sekhavat et al. · 2019 [cited by applicant]
US 11253518B2 · Wurst · 2022 [cited by examiner]
US 20020077256A1 · Niemiec et al. · 2002 [cited by applicant]
US 20040082660A1 · Ueno · 2004 [cited by applicant]
US 20040115234A1 · Gewirtz · 2004 [cited by applicant]
US 20050079139A1 · Jacques et al. · 2005 [cited by applicant]
US 20070160562A1 · Brinkenhoff · 2007 [cited by applicant]
US 20080206156A1 · Cronk · 2008 [cited by applicant]
US 20100204335A1 · Beddingfield et al. · 2010 [cited by applicant]
US 20100210720A1 · Pilotaz et al. · 2010 [cited by applicant]
US 20120129789A1 · Yoelin · 2012 [cited by applicant]
US 20130041025A1 · Walt et al. · 2013 [cited by applicant]
US 20140322148A1 · Jackson · 2014 [cited by applicant]
US 20150072963A1 · Cotsarelis et al. · 2015 [cited by applicant]
US 20150164765A1 · Yoelin · 2015 [cited by applicant]
US 20150328108A1 · Trogden · 2015 [cited by examiner]
US 20160136071A1 · Corboy, Jr. · 2016 [cited by applicant]
US 20160213590A1 · Sekhavat et al. · 2016 [cited by applicant]
US 20160346183A1 · Sekhavat · 2016 [cited by applicant]
US 20170181950A1 · Wu · 2017 [cited by applicant]
US 20180200263A1 · Grimes · 2018 [cited by applicant]
US 20210038601A1 · Wurst · 2021 [cited by applicant]
US 20210038683A1 · Wurst · 2021 [cited by applicant]
CA 2309373A1 · 2000 [cited by applicant]
EP 3494955A1 · 2019 [cited by applicant]
JP 2001002535A · 2001 [cited by applicant]
JP 2001511155A · 2001 [cited by applicant]
JP 2003155218A · 2003 [cited by applicant]
JP 2014510042A · 2014 [cited by applicant]
WO 1998033497A1 · 1998 [cited by applicant]
WO 2005013928A1 · 2005 [cited by applicant]
WO 2007023841A1 · 2007 [cited by applicant]
WO 2009151828A1 · 2009 [cited by applicant]
WO 2011081861A2 · 2011 [cited by applicant]
WO 2012106249A2 · 2012 [cited by applicant]
WO 2013078259A2 · 2013 [cited by applicant]
WO 2013106565A1 · 2013 [cited by applicant]
WO 2015176161A1 · 2015 [cited by applicant]
WO 2019034571A1 · 2019 [cited by applicant]
De Prost et al., “Treatment of severe alopecia areata by topical applications of cyclosporin A: comparative trial versus placebo in 43 patients,” in “Trends in Human Hair Growth and Alopecia Research” by van Neste et al… [cited by examiner]
Gilhar et al., “Topical cyclosporine in male pattern alopecia,” J. Am. Acad. Dermatol. 1990;22(2 Pt 1):251-53. PMID: 2312805. (Year: 1990). [cited by examiner]
Osborne, David; Skin Penetration and Permeation Properties of Transcutol®—Neat or Diluted Mixtures, AAPS PharmSciTech, vol. 19, No. 8, Nov. 2018, pp. 3513-3533. [cited by applicant]
Williams, et al., “Penetration Enhancers”, 2004, Advanced Drug Delivery Reviews, 56(5), pp. 603-618. (doc.org/10.1016/j.addr.2003.10.025) (Year: 2004). [cited by applicant]
McCarey et al. “Low Incidence of Iris Pigmentation andEyelash Changes in 2 Randomized Clinical Trials with Unoprostone Isopropyl 0.15%” American Academy of Opthalmology, pp. 1480-1488, 2004. [cited by applicant]
Aditya Gupta, et al., Efficacy of Off-Label Treatments for the Management of Androgenetic Alopecia: A Review, Clinical Drug Investigation, Jan. 2019, 8 pages. [cited by applicant]
Ahmed Abdulhussein Kawen, Topical Minoxidil alone and with Lanoprost in Localized Alopecia Areata Treatment: Comparative Study (2019-2020), Systematic Review Pharmacy, vol. 11, Issue 4, pp. 164-169, 2020. [cited by applicant]
Amal Ahmad El-Ashmawy, et al, Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata, Journal of Dermatological Treatment, vol. 29, No. 1, Jun. 15, 2017, pp. 55-6… [cited by applicant]
Bloch et al., Latanoprost and minoxidil: Comparative double-blind , placebo-controlled study for the treatment of hair loss, Surg Cosmet Dermatol. Rio de Janeiro v.10 n.1 Jan-Mar. 2018 p. 39-43, DOI: http://dx.doi.org/1… [cited by applicant]
Clinical Investigation, A Prospective Study of Iridial Pigmentation and Eyelash Changes Due to Ophthalmic Treatment with Latanoprost, Japanese Journal of Ophthalmology, Mar. 2004, vol. 48, Issue 2, pp. 141-147 (first on… [cited by applicant]
Coleman, H., The Cosmetic Effects of Bimatoprost vs. Latanoprost vs. Travoprost vs. Placebo on Eyelash Growth. American Academy of Optometry, 2010, 3 pages. [cited by applicant]
Edited by Rowe et al., (2009), “Handbook of Pharmaceutical Excipients (6th ed.)”, London: APhA, (PhP) Pharmaceutical Press., pp. 468-470. (Year: 2009). [cited by applicant]
Feidler-Weiss, Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata, Journal of American Academy of Dermatology, vol. 16, No. 3, part 2, pp. 745-748, Mar. 1987. [cited by applicant]
Garg et al, Alpoecia areata: edivence-based treatments, Semin Cutan Med Sug., Mar. 2009, one page. [cited by applicant]
Gita Faghihi, et al, The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows, Eur J Dermatol, 2009; 19, pp. 586-587. [cited by applicant]
Hawkshaw et al., Identifying novel strategies for treating human hair loss disorders: Cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles, PLOS Biology Fifteenth Anniv… [cited by applicant]
Hideo Uno et al, Effect of Latanoprost on Hair Growth in the Bald Scalp of the Stump-tailed Macacque: A Pilot Study, Acta Derm Venereol, 2002, pp. 7-12. [cited by applicant]
Im Coronel-Perez, et al, Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis, DJEADV, 2010, No. 24, pp. 481-485. [cited by applicant]
Johnstone et al., Prostaglandin-Induced Hair Growth, Survey of Ophthalmology, vol. 47, supplement 1, Aug. 2002. [cited by applicant]
Jorge Ocampo-Garza, et al, New drugs under investigation for the treatment of alopecias, Expert Opinion on Investigational Drugs, Issn 1354-3784, Jan. 15, 2019, 34 pages. [cited by applicant]
Justine A. Ellis, et al., Male pattern baldness: current treatments, future prospects, Drug Discovery Today, vol. 13, No. 17/18, Sep. 2008, pp. 791-797. [cited by applicant]
Karzan G. Khidir, et al, The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias, The FASEB Journal, 27 (2), Feb. 2013, pp. 557-567. [cited by applicant]
Lauren L. Levy, et al, Female pattern alopecia: current perspectives, International Journal of Women's Health, Aug. 28, 2013, pp. 541-556. [cited by applicant]
Murad, et al, Treatment for facial alopecia areata: A systematic review with evidence-based analysis, Journal of American Dermatology, Apr. 14, 2017, 10 pages. [cited by applicant]
National Center for Biotechnology Information. “PubChem Compound Summary for CID 8146, Diethylene glycol monoethyl ether” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Diethylene-glycol-monoethyl-ether. Created Mar… [cited by applicant]
Ozyurt S., et al, Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost, Actas Dermosifiliogr, 2015, pp. 74-75. [cited by applicant]
Patel et al., Bioanalytical Method Development and Validation for Latanoprost Quantification in Pharmaceutical Opthalmic Microemulsion Formulation by RP-HPLC, Journal of Analytical & Bioanalytical Techniques, vol. 6, is… [cited by applicant]
Paula M. Oliveira, et al, LC-MS bioanalytical method for simultaneous determination of latanoprost and minoxidil in the skin, Journal of Pharmaceutical and Biomedical Analysis, Mar. 6, 2020, 26 pages. [cited by applicant]
Pfizer Manufacturing Belgium NV, Xalatan Package Insert for the 2.5 mL fill—Package of 1 Bottle, Aug. 2011, 14 pages. [cited by applicant]
Rajarshi Mukhopadhyay, et al, A rare complication from prostaglandin analogue therapy, Clinical and Experimental Optometry, 2009, 92:2, pp. 137-138. [cited by applicant]
S. Sasaki, et al, Influence of prostaglandin F2a and its analogues on hair regrowth and follicular melanogenesis in a murine model, Experimental Dermatology, 2005, pp. 323-328. [cited by applicant]
Sardesai et al, A Study to Evaluate the Efficacy of Various Topical Treatment Modalities for Alopecia Areata, International Journal of Trichology, Oct.-Dec. 2012, 4 (4), pp. 265-270. [cited by applicant]
Schweiger et al., Topical Bimatoprost for the Treatment of Eyebrow Hypotrichosis, Journal of Drugs in Dermatology, vol. II, Issue I, Jan. 2012, 106-108. [cited by applicant]
T. Ogiso, et al. Transfollicular Drug Delivery: Penetration of Drugs Through Human Scalp Skin and Comparison of Penetration Between Scalp and Abdominal Skins In Vitro, Journal of Drug Targeting, 2002, vol. 10 (5), pp. 3… [cited by applicant]
Ulrike Blume-Peytavi, et al., A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with… [cited by applicant]
Y. Liang et al, Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variat complexes, British Journal of Pharmacology, 2008, pp. 1079-1093. [cited by applicant]
Williams, Penetration Enhancers, Advance Drug Delivery Reviews, 56(5), pp. 603-618, (doi.org/10.1016/jaddr.2003.10.25) (year 2004). [cited by applicant]